Wenge Zhong
Co-Founder and CTO,
Regor Therapeutics
United States
Dr. Wenge Zhong, cofounder and CTO of Regor Therapeutics Group, is a seasoned drug hunter in multiple therapeutic areas. He built the industry leading Computer Accelerated Rational Discovery – rCARD – technology platform at Regor and leveraged its power to dramatically accelerate all discovery programs and deliver numerous best-in-class and/or first-in-class development candidates. Dr. Zhong is the inventor of the unique next-gen CDK4+ inhibitor RGT-419B for breast cancer, the world-leading oral small molecule GLP1R full agonist RGT-075 for obesity, and the many others including RGT-028, RGT-274, RGT-264, and RGT-118 for metabolic disorders, immuno-oncology, and autoimmune diseases.
Prior to Regor, Dr. Zhong built and led the discovery team at Amgen Asia R&D Center in Shanghai and established the GPCR Structural Biology, the GPCR nanobody discovery, and the DEL technology platforms. Dr. Zhong received his BS degree from Peking University, PhD degree from the California Institute of Technology, and postdoctoral training at the Scripps Research Institute. He is a coauthor or co-inventor of more than 70 publications and patent applications. Throughout his career, Dr. Zhong has led successful collaborations with industry partners and academic institutions, has served as industry mentor to undergraduate and graduate students at world-renowned universities.
Sessions
-
11-Feb-2025PlymouthRegor Therapeutics
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}